United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 8

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 8 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderInspire Medical · 43

Strongest available pathSi-Bone · -11.7%

Widest latest marginInspire Medical · 15.9%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1INSP · NYSE

Inspire Medical

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2007Maple Grove, Minnesota$1.78B market cap

View full Companies Radar profile

43Cautious

Snapshot price$61.52as of page date

Monthly-close return-73.6%five-year window

FY2025 revenue$0.91BInspire Medical Systems, Inc.

Net margin15.9%FY2025

P/E snapshot13.6xone ratio, not a verdict

Prism attention72.0%share across these five

Filing track recordRevenue, USD billions

+290.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 40.6%

52-week position21% through range

$38.91$147.0

News mentions13.5K

Community mentions56partial coverage

U.S.-scope patents464

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal56/100
Management stability90/100
Market position3/100
Capital-event signal63/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 2 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2SIBN · Nasdaq

Si-Bone

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2008San Jose, California$839.1M market cap

View full Companies Radar profile

43Cautious

Snapshot price$18.92as of page date

Monthly-close return-11.7%five-year window

FY2025 revenue$0.20BSI-BONE, Inc.

Net margin-9.4%FY2025

P/E snapshot-57.2xone ratio, not a verdict

Prism attention4.1%share across these five

Filing track recordRevenue, USD billions

+122.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.2%

52-week position71% through range

$11.48$21.89

News mentions777

Community mentions14partial coverage

U.S.-scope patents17

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal66/100
Management stability90/100
Market position0/100
Capital-event signal34/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3IART · Nasdaq

Integra LifeSciences

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1989Plainsboro, New Jersey$1.29B market cap

View full Companies Radar profile

42Cautious

Snapshot price$16.62as of page date

Monthly-close return-75.7%five-year window

FY2025 revenue$1.64BINTEGRA LIFESCIENCES HOLDINGS CORP

Net margin-31.6%FY2025

P/E snapshot6.4xone ratio, not a verdict

Prism attention16.4%share across these five

Filing track recordRevenue, USD billions

+6.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.5%

52-week position67% through range

$8.70$20.49

News mentions3.1K

Community mentions13partial coverage

U.S.-scope patents279

Prism InsightsWhat sits behind the readiness signal
Observed risk 8/100higher means more observed risk

Earnings signal55/100
Management stability90/100
Market position24/100
Capital-event signal39/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 43 M&A involvements, 3 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 0 regulatory and 1 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4MDXG · Nasdaq

MiMedx Group

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1985Marietta, Georgia$658.8M market cap

View full Companies Radar profile

42Cautious

Snapshot price$4.52as of page date

Monthly-close return-25.4%five-year window

FY2025 revenue$0.42BMIMEDX GROUP, INC.

Net margin11.6%FY2025

P/E snapshot113.0xone ratio, not a verdict

Prism attention5.7%share across these five

Filing track recordRevenue, USD billions

+61.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.8%

52-week position30% through range

$3.03$7.97

News mentions1.1K

Community mentions9partial coverage

U.S.-scope patents431

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal41/100
Management stability90/100
Market position7/100
Capital-event signal57/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5OBIO · NASDAQ

Orchestra BioMed

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2017New Hope, Pennsylvania$294.5M market cap

View full Companies Radar profile

40Cautious

Snapshot price$4.90as of page date

Monthly-close return-50.5%five-year window

FY2025 revenue$0.03BOrchestra BioMed Holdings, Inc.

Net margin-157.4%FY2025

P/E snapshot-3.2xone ratio, not a verdict

Prism attention1.8%share across these five

Filing track recordRevenue, USD billions

+1113.1%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 248.3%

52-week position75% through range

$2.20$5.78

News mentions334

Community mentions4partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position3/100
Capital-event signal46/100
Innovation pulse8/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 4 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Si-Bone

-11.7%

MiMedx Group

-25.4%

Orchestra BioMed

-50.5%

Inspire Medical

-73.6%

Integra LifeSciences

-75.7%

Latest revenue

USD billions, official filing scope shown on each company card.

Integra LifeSciences

$1.64B

Inspire Medical

$0.91B

MiMedx Group

$0.42B

Si-Bone

$0.20B

Orchestra BioMed

$0.03B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Inspire Medical

15.9%

MiMedx Group

11.6%

Si-Bone

-9.4%

Integra LifeSciences

-31.6%

Orchestra BioMed

-157.4%

Prism news attention

Normalized share across these five names; attention is not quality.

Inspire Medical

72.0%

Integra LifeSciences

16.4%

MiMedx Group

5.7%

Si-Bone

4.1%

Orchestra BioMed

1.8%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Inspire Medical leads the conversation

It holds 72.0% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $0.91B.

Price path

Si-Bone leads the available price paths

Its monthly-close return is -11.7% for the five-year window. At the other end, Integra LifeSciences is -75.7% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Inspire Medical has the widest latest margin

Its FY2025 net margin is 15.9%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Si-Bone shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -57.2x while its five-year window price return is -11.7%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · INSP

Inspire Medical

13,547available Prism news records

Prism top themes

Leadership & governance

Earnings & financial performance

Price action & investor response

Legal, arbitration & regulatory

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-0.3%1,531 latest 12m vs 1,536 prior 12m

Machine-classified coverage tone

83.3% positive-1.2 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

electronic document management 48legal document management 43document workflow systems 41biomarkers early lung cancer 29screening eligibility lung cancer 29bariatric surgery sleep apnea 29lung cancer risk assessment 28stock performance 28

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · IART

Integra LifeSciences

3,074available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Leadership & governance

Capital allocation & transactions

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+12.2%396 latest 12m vs 353 prior 12m

Machine-classified coverage tone

96.3% positive+0.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 17earnings report 16quarterly results 16annual earnings 15biomaterials 12stock indices 11tissue regeneration 10new executive 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-19–2026-06-11 · trend and themes shown through 2026-06

Areas of research · MDXG

MiMedx Group

1,067available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-19.2%97 latest 12m vs 120 prior 12m

Machine-classified coverage tone

86.8% positive-5.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

earnings report 11financial report 9stock performance 8stock price 7annual earnings 7share price 7device-biologic combination 6tissue regeneration 4

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-02–2026-06-02 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

INSP

Inspire Medical

56 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 56 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

INSP

Inspire Medical

through 2026-05-04

Earnings releases 45Leadership changes 9Lawsuits 8

2026-05-04
Earnings releases
Inspire Medical Systems (NYSE:INSP – Get Free Report) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.750-1.250 for the period, compared to the consensus earnings per share estimate of 1.990. The company issued revenue guidance of $825.0 million-$875.0 million, compared to the consensus revenue estimate of $961.2 million.
2026-02-17
Lawsuits
An investor, who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP), filed a lawsuit over alleged violations of Federal Securities Laws by Inspire Medical Systems, Inc.
2026-01-12
Leadership changes
Inspire Medical (NYSE: INSP) + announced today that it appointed Matt Osberg as its new EVP and chief financial officer (CFO).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SIBN

Si-Bone

through 2026-01-12

Earnings releases 25Company announcements 1Listing / IPO 1

2026-01-12
Earnings releases
Worldwide revenue between $200.8 - $200.9 million, representing ~20% growth
2023-05-06
Company announcements
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, has announced the pricing of its underwritten public offering of 3,775,000 shares of its common stock at a price to the public of US$22.00.
2023-05-05
Listing / IPO
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the pricing of its underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $22.00.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IART

Integra LifeSciences

through 2026-02-26

Earnings releases 32Lawsuits 17Leadership changes 15M&A 8Company announcements 3

2026-02-26
Earnings releases
Full-Year 2025 Reported revenues were $1,635.2 million, representing an increase of 1.5% on a reported basis and a decrease of 0.7% on an organic basis compared to full-year 2024.
2026-02-18
Leadership changes
Integra LifeSciences Holdings Corporation, a leading global medical technology company in Princeton, announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company.
2025-02-14
Regulatory
Integra LifeSciences Corp., of Plainsboro, N.J.,received FDA approval to export its Integra Artifical Skinto Denmark. The product, which is under review by the FDA for marketing in the U.S., is used to restorefunctional dermal tissue in critically burned patients.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MDXG

MiMedx Group

through 2026-04-16

Earnings releases 15Leadership changes 11Business contracts 3Company announcements 1Lawsuits 1

2026-04-16
Leadership changes
As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated.
2025-10-30
Earnings releases
Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year
2025-02-13
M&A
Alynx (Salt Lake City) completed its acquisition of MiMedx (Tampa, Florida), a development-stage company focusing on biomaterials for soft tissue repair.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

OBIO

Orchestra BioMed

through 2026-03-12

Company announcements 8Earnings releases 6Leadership changes 2M&A 1

2026-03-12
Earnings releases
today reported its full year 2025 financial results and provided a fourth quarter business update.
2026-02-13
Company announcements
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), ... reported today that, on February 12, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 120,000 shares of the Company’s common stock to nine newly hired employees.
2024-03-26
Leadership changes
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), today announced the appointment of David Pacitti to its Board of Directors, effective as of March 26, 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 36–43. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Inspire Medical leads the readiness ranking

Its Prism readiness score is 43/100, the highest in this five-company comparison.

Open Inspire Medical in Companies Radar

Scale and margin leadership sit with Integra LifeSciences and Inspire Medical

Integra LifeSciences has the largest displayed latest revenue at $1.64B; Inspire Medical has the widest displayed latest margin at 15.9%.

Open Integra LifeSciences in Companies Radar Open Inspire Medical in Companies Radar

Comparisons

Strongest versus weakest available price path

Si-Bone is -11.7% for its five-year window; Integra LifeSciences is -75.7% for its five-year window.

Open Si-Bone in Companies Radar Open Integra LifeSciences in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $1.64B for Integra LifeSciences to $0.03B for Orchestra BioMed. Entity and filing-period labels remain visible on the company cards.

Open Integra LifeSciences in Companies Radar Open Orchestra BioMed in Companies Radar

Anomalies

Si-Bone has the widest attention-readiness rank gap

It ranks #4 by measured news attention (4.1%) and #2 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Si-Bone in Companies Radar

Orchestra BioMed shows a price-operating divergence to inspect

Its displayed filing-revenue change is +1113.1% while its available monthly-close return is -50.5%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Orchestra BioMed in Companies Radar

Explanations

Attention measures coverage volume, not quality

Inspire Medical's 72.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Inspire Medical in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Inspire Medical's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 43/100 score.

Open Inspire Medical in Companies Radar

Stress-test the largest divergence before forming a view

Compare Orchestra BioMed's profile with Si-Bone's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Orchestra BioMed in Companies Radar Open Si-Bone in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.